TY - JOUR T1 - Role of PCA3 and SelectMDx in the optimization of active surveillance in prostate cancer JO - Actas Urológicas Españolas (English Edition) T2 - AU - Fiorella,D. AU - Marenco,J.L. AU - Mascarós,J.M. AU - Borque-Fernando,Á. AU - Esteban,L.M. AU - Calatrava,A. AU - Pastor,B. AU - López-Guerrero,J.A. AU - Rubio-Briones,J. SN - 21735786 M3 - 10.1016/j.acuroe.2020.10.013 DO - 10.1016/j.acuroe.2020.10.013 UR - https://www.elsevier.es/en-revista-actas-urologicas-espanolas-english-392-articulo-role-pca3-selectmdx-in-optimization-S2173578621000767 AB - Introduction & objectivesA not negligible percentage of patients included in active surveillance (AS) for low and very low risk prostate cancer (PCa) are reclassified in the confirmatory biopsy or have disease progression during follow-up. Our aim is to evaluate the role of PCA3 and SelectMDx, in an individual and combined way, in the prediction of pathological progression (PP) in a standard AS program. Materials & methodsProspective and observational study comprised of 86 patients enrolled in an AS program from 2009 to 2019, with results for PCA3 and SelectMDx previous to PCa diagnosis or during their confirmatory period. Univariate and multivariate analysis were performed to correlate PCA3 and SelectMDx scores as well as clinical and pathological variables with PP-free survival (PPFS). The most reliable cut-offs for both biomarkers in the context of AS were defined. ResultsSelectMDx showed statistically significant differences related to PPFS (HR 1.035, 95%CI: 1.012−1.057) (p = 0.002) with a C-index of 0.670 (95%CI: 0.529−0.810) and AUC of 0.714 (95%CI: 0.603−0.825) at 5 years. In our series, the most reliable cut-off point for SelectMDx was 5, with a sensitivity and specificity for PP of 69.8% and 67.4%, respectively. Same figure for PCA3 was 65, with a sensitivity and specificity for PP of 51.16% and 74.42%, respectively. The combination of both biomarkers did not improve the prediction of PP, C-index 0.630 (95%CI: 0.455−0.805). ConclusionsIn the context of low or very low risk PCa, SelectMDx > 5 predicted 5 years PP free survival with a moderate discrimination ability outperforming PCA3. The combination of both tests did not improved outcomes. ER -